Company intelligence / Profile preview
Anocca
Södertälje, Stockholms län, Swedenanocca.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Anocca received CTA approval in March 2025 for its first-in-human VIDAR-1 trial testing ANOC-001 in advanced pancreatic cancer. The trial will be conducted in Sweden, Denmark, Germany, and The Netherlands, with initiation planned for Q2 2025. This marks Anocca's transition to a clinical-stage company and is the first regulatory authorization in Europe to study a non-viral gene-edited TCR-T therapy.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- T-cell receptor-engineered T cell (TCR-T) therapies
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
Shinobi Therapeutics
Beyond the preview
Go deeper on Anocca.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anocca.